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with notable resource utilization, including inpatient admissions. Average total 
per patient costs associated with potential AEs constituted over 10% of total 
costs.  
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OBJECTIVES: To assess the clinical characteristics and economic burden of 
patients diagnosed with the hepatitis C virus (HCV) in the U.S. veteran 
population. METHODS: A retrospective database analysis was performed using 
the Veterans Health Administration (VHA) Medical SAS Datasets from October 1, 
2005 to May 31, 2012. All U.S. veteran beneficiaries diagnosed with HCV were 
identified using International Classification of Disease 9th Revision Clinical 
Modification (ICD-9-CM) diagnosis codes 070.41, 070.44, 070.51, 070.54, and 
V02.62. Comorbidities and other clinical conditions were assessed for the 12-
month baseline period. Health care resource utilization and costs were assessed 
for the 12-month follow-up period. Descriptive statistics were calculated as 
means ± standard deviation (SD) and percentages to measure cost, and 
utilization distribution in the sample. RESULTS: A total of 146,161 veterans were 
diagnosed with HCV during the study period. Among the 10 most common 
baseline comorbidities, hypertension was the only condition comprising of more 
than 20% of patients. Patients were also diagnosed with comorbid lumbago 
(8.26%), presbyopia (3.93%) and backache (3.80%), which are common in the 
elderly population. During the baseline period, 4172 patients (or approximately 
3% of the patient population) had Albumin test results of <3.0 mg/dl. 15.03% of 
patients had Prolonged Prothrombin Time Test results of >3.0 seconds. 
Omeprazole (16.06%), lisinopril (15.86%) and hydrochlorothiazide (10.88%) were 
the most commonly prescribed medications within 60 days of initial disease 
identification. Inpatient (26.84%), emergency room (ER) (30.06%), office (99.78%), 
outpatient (99.81%) and pharmacy visits (93.65%) were calculated. Health care 
utilizations translated to the following health care expenses: inpatient ($9,841, 
SD $38,442), ER ($393, SD $1,042), office visit ($9,587, SD $13,035), outpatient 
($10,169, SD $13,599), and pharmacy costs ($1,771, SD $4,703). CONCLUSIONS: 
HCV treatment is complicated by the presence of comorbidities such as 
hypertension. Further analysis of complicated comorbid conditions is required to 
improve the overall burden of illness of HCV patients.  
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OBJECTIVES: To assess the population-level impact and cost-effectiveness of 
universal Hepatitis A vaccination of children in United States as recommended 
by Advisory Committee on Immunization Practices (ACIP) in 2006 compared with 
the prior ACIP regional policy of routine vaccination of children living in states 
with high hepatitis rates. METHODS: We developed a population-dynamic model 
of Hepatitis A to evaluate the public health- and economic- impacts of two-dose 
Hepatitis A vaccination of children 12 and 18 months of age. The dynamic model 
was fitted to Hepatitis A seroprevalence from the National Health and Nutrition 
Examination Survey (NHANES II and III) and reported incidence from the 
National Notifiable Diseases Surveillance System (1980–1995). We used a societal 
perspective and projected outcomes over the period 2006–2106 (a 100-year time 
horizon). Both costs and quality-adjusted life years (QALYs) were discounted at 
3% per year. RESULTS: Universal Hepatitis A vaccination prevented 144,375 
infections, 63,153 outpatient visits, 2,727 hospitalizations, and 96 deaths 
incrementally on an average annual basis when compared to the regional 
vaccination policy. Herd protection played an important role in reducing 
infections as it accounted for prevention of nearly 76% of deaths and 50% of 
outpatient visits and hospitalizations. Ignoring herd protection, vaccination 
prevented 90,845 infections, 34,353 outpatient visits, 1,438 hospitalizations, and 
23 deaths annually. Taking herd protection into account, universal vaccination 
was cost saving, whereas without it the ICER was $41,712/QALY. CONCLUSIONS: 
Universal two-dose vaccination of children led to significant reductions in 
Hepatitis A mortality and morbidity. Consequently, universal vaccination was 
cost saving compared with a regional vaccination policy. Herd protection effects 
of vaccination programs had a significant impact on hepatitis A mortality, 
morbidity, and cost-effectiveness ratios. Because of their ability to capture the 
natural phenomenon of herd protection, dynamic models have significant utility 
for economic evaluation of Hepatitis A vaccination programs.  
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OBJECTIVES: In 2011 PCV13 replaced PCV7 in Costa Rica’s National 
Immunization Program, however, continuation of the program is being evaluated 
based on considerations of cost-effectiveness. We evaluated the cost-
effectiveness of continuing universal PCV13 infant vaccination versus limiting 
vaccination to high-risk children. METHODS: We used a decision-analytic 
Markov model to assess the impact of alternative pediatric PCV13 vaccination 
strategies: universal versus targeted to high-risk children only. For the universal 
strategy, outcomes are assessed for the entire Costa Rican population to capture 
indirect (herd) effects that accrue in the unvaccinated individuals. The model 
was populated using Costa Rican epidemiologic data and estimates from other 
published sources. Estimates of PCV13 effectiveness were extrapolated from 
observed PCV7 data, using assumptions regarding serotype prevalence and 
PCV13 protection against 6 additional serotypes. Coverage was assumed to be 
the same for high-risk and the general population vaccination strategies. 
Outcome measures were incidence of invasive pneumococcal disease (IPD), 
pneumonia and acute otitis media (AOM); mortality, and net medical-care costs 
over 10 years from the societal perspective. RESULTS: Compared to no 
vaccination, the high-risk program would prevent 100 cases of IPD, 420 cases of 
hospitalized pneumonia (HP), 330 cases of non-hospitalized pneumonia (NHP), 
and 26,300 cases of AOM, and provide net savings of $460,000 over 10 years. 
Universal vaccination would prevent 2,200 cases of IPD, 14,800 cases of HP, 
24,500 cases of NHP, and 367,000 cases of AOM for net savings of $34.8 million. 
Compared to the high-risk program, universal vaccination would provide net 
savings of $34.3 million. Excluding indirect effects, universal vaccination results 
in ICERs of $4,400 and $5,600 per QALY gained compared with no vaccination 
and high-risk vaccination, respectively. CONCLUSIONS: Both high-risk and 
universal infant vaccination with PCV13 are cost-effective in Costa Rica; 
universal vaccination dominates both no vaccination and high risk vaccination 
due to indirect effects.  
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OBJECTIVES: Complicated skin and soft tissue infections (cSSTI) are commonly 
encountered in the community and nosocomial settings. Methicillin-resistant S. 
aureus (MRSA) has become the predominant pathogen in cSSTI raising health 
care costs and reducing positive health outcomes. The aim of this analysis is to 
estimate the cost-effectiveness of linezolid in the treatment of cSSTI in Chile 
from the private payer’s perspective. METHODS: A decision tree was built  
to estimate the incremental cost-effectiveness ratio (ICER) of linezolid (1200 
mg/day) compared with vancomycin (2 mg/day), daptomycin (350 mg/day) and 
tigecycline (100 mg/day). Within a time horizon of 28 days, the model simulates 
health outcomes and costs for all alternatives at the Provisional Health 
Institutions – ISAPRE. Only direct medical costs were considered. Effectiveness 
measures were: quality-adjusted life-year gained (QALY’s) and percentage of 
patients cured. Efficacy, safety and utility values were collected from literature 
review. Resource use and medical costs (drug acquisition, inpatient stay, health 
care professional visits, and lab tests) were taken from Chilean private 
institutions. Costs are expressed in 2012 US$. RESULTS: The total expected  
costs for per patient were: linezolid US$12,905.1, vancomycin US$13,039.9, 
daptomycin US$16,067.3 and tigecycline US$17,038.5. Treatment with linezolid 
was associated with a shorter length of stay at the intensive care unit (7 days on 
average) which reduced significant treatment costs due the likelihood of 
switching from intravenous to oral administration (5 days savings on average). 
Results for each alternative in terms of QALYs were: linezolid 0.063, vancomycin 
0.060, daptomycin 0.061 and tigecycline 0.059. The percentage of patients  
cured for each alternative was: linezolid 84.4%; vancomycin 74.7%; daptomycin 
78.1% and tigecycline 70.4%. Model result suggests that linezolid would be 
dominant compared to vancomycin, daptomycin and tigecycline. 
CONCLUSIONS: Despite its higher acquisition cost, linezolid would be a cost-
saving alternative in the treatment of cSSTI in the Chilean Provisional Health 
Institutions (ISAPRE).  
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OBJECTIVES: Complicated skin and skin structure infections (cSSSIs) are 
primarily caused by gram-positive bacteria, including Staphylococcus aureus and 
β-hemolytic streptococci. The impact of cSSSIs caused by Methicillin-resistant S. 
aureus (MRSA) has been associated with an increase in length of hospital stay 
and resource use. The aim of this analysis is to estimate the cost-effectiveness of 
linezolid in the treatment of cSSTI at the Chilean public setting. METHODS: A 
decision tree was built to estimate the incremental cost-effectiveness ratio of 
linezolid (1200 mg/day) compared to vancomycin (2 mg/day), daptomycin (350 
mg/day) and tigecycline (100 mg/day). The payer’s perspective (National Fund of 
Health – FONASA) was used, including inpatient medical costs only. The time 
horizon was 28 days. Effectiveness was measured with quality-adjusted life-year 
(QALY’s) and the percentage of patients cured. Efficacy, safety and utility values 
were retrieved from literature. Resource use and costs (drug acquisition, 
inpatient stay, health care professional visits, and lab tests) were taken from 
Chilean public health care institutions. Costs are expressed in 2012 USD. 
RESULTS: The total expected costs per patient were: linezolid US$3489.0, 
